

Molecular Cancer Therapeutics



Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors

Michael C Heinrich, Adrian Marino-Enriquez, Ajia Presnell, et al.

Mol Cancer Ther Published OnlineFirst June 4, 2012.

Updated Version

Access the most recent version of this article at:
doi:[10.1158/1535-7163.MCT-12-0223](https://doi.org/10.1158/1535-7163.MCT-12-0223)

Author Manuscript

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts

[Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors

Michael C. Heinrich¹, Adrian Marino-Enriquez², Ajia Presnell¹, Rachel S. Donsky², Diana J. Griffith¹, Arin McKinley¹, Janice Patterson¹, Takahiro Taguchi³, Cher-Wei Liang², Jonathan A. Fletcher²

¹Portland VA Medical Center and OHSU Knight Cancer Institute, Portland, OR, USA,

²Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA, and

³Kochi University, Kochi, Japan.

Correspondence to:

Michael C. Heinrich, MD (AACR # 81587)
Division of Hematology/Oncology
Departments of Medicine and Cell and Developmental Biology
Portland VA Medical Center and OHSU Knight Cancer Institute, Oregon Health & Science University
R&D-19 3710 U.S. Veterans Hospital Road
Portland, OR 97239
Tel.: (503) 220-3405
Fax: (503) 273-5158
E-mail: Heinrich@ohsu.edu

Running title: Sorafenib inhibits kinase mutations in drug resistant GIST

Conflict of interest information for Dr. Michael Heinrich: Consultant (Novartis, MolecularMD, Pfizer), Research Grant support (Novartis, AROG, Imclone/Lilly, Ariad), Equity interest (Molecular MD). Acknowledgement: Dr. Heinrich's COI are managed by OHSU and Portland VA COI committees.

Abstract

Sorafenib has substantial clinical activity as third- or fourth-line treatment of imatinib- and sunitinib-resistant GI stromal tumors (GIST). Because sorafenib targets both angiogenesis-related kinases (VEGFRs) and the pathogenetic kinases found in GIST (KIT or PDGFRA), the molecular basis for sorafenib efficacy in this setting remains unknown. We sought to determine the spectrum of activity of sorafenib against different mutant kinases associated with drug-sensitive and drug-resistant GIST. We compared the activity of imatinib and sorafenib against transiently expressed mutant forms of KIT and PDGFRA, including various secondary mutations that have been identified in imatinib-resistant or sunitinib-resistant GISTs. We also examined these drugs against 4 GIST cell lines, 3 of which are imatinib resistant. In our in vitro studies, we determined that sorafenib inhibited imatinib-resistance mutations in exons encoding the ATP/drug binding pocket, and in exons encoding the activation loop, with the exception of substitutions at KIT codon D816 and PDGFRA codon 842. Notably our data indicate that sorafenib is more effective than imatinib or sunitinib for inhibiting the kinase activity of drug resistant KIT mutants (as assessed by biochemical IC_{50}). We hypothesize that a major determinant of the efficacy of sorafenib for treatment of advanced GIST is the activity of this agent against KIT or PDGFRA mutant kinases. These results have implications for the further development of treatments for drug-resistant GIST.

Introduction

Activating mutations of receptor tyrosine kinases KIT or PDGFRA are key to the pathogenesis of most GI stromal tumors (GISTs). More than 80% of GISTs express mutated, constitutively active KIT receptors, another 5% to 7% express mutated PDGFRA, and the remaining 10% to 15% are wild-type GISTs (WT) lacking mutations in either of these kinases.(1, 2)

Imatinib mesylate, a small molecule kinase inhibitor with potent activity against KIT and PDGFRA, has revolutionized GIST treatment and is now well established as front-line medical treatment for advanced disease. Despite very high rates of disease control with this agent, up to 50% of patients suffer disease progression within 2 years of initiating therapy, and the vast majority of patients eventually develop drug resistant disease.(3, 4) In the majority of cases, the tumor regrowth occurs after an initial response, becoming radiologically evident more than 6 months after beginning treatment (delayed or secondary resistance). However, 10-15% of patients have tumors that exhibit primary imatinib resistance, defined as progression with 3-6 months of starting therapy.(5)

There are distinct molecular mechanisms underlying primary and secondary imatinib resistance. Primary resistance is typically found in GISTs with specific genotypes: KIT exon 9 mutation, PDGFRA D842V mutation, or WT GIST. Resistance in this setting is probably due to relative or absolute resistance of these kinases to imatinib at clinically achievable drug levels.(6) In the case of exon 9 mutant-GIST, evidence from phase 3

studies indicates that the probability of primary resistance can be reduced by using a higher dose of imatinib.(4) Most cases of secondary resistance are associated with an acquired kinase mutation of the ATP/drug binding pocket or the kinase activation loop on the same allele (cis-conformation) as the primary activating mutation.(5, 7, 8) Such secondary mutations are rare in cases of primary imatinib resistance.

Sunitinib, another small-molecule tyrosine kinase inhibitor (TKI) with selectivity for KIT and PDGFRA (as well as PDGFRB, all three isoforms of vascular endothelial growth factor receptor [VEGFR], FMS-like tyrosine kinase 3 [FLT3], and colony-stimulating factor 1 receptor [CSF-1R]) has demonstrated clinical benefit in phase 1-3 trials with patients who were intolerant of imatinib or had disease that was imatinib-resistant.(6, 9, 10) Sunitinib has been approved for treatment of GIST patients for whom prior imatinib therapy failed due to disease progression or drug intolerance. Unfortunately, the median progression free survival with second-line sunitinib is only 6-7 months.(9) Profiling of sunitinib against imatinib-resistant kinases (i.e. KIT with primary + secondary mutations) has shown that sunitinib potently inhibits imatinib-resistant KIT ATP/drug binding pocket mutations, but has little activity against imatinib-resistant KIT activation loop mutations.(6, 11, 12) Thus, many imatinib-resistant mutations confer cross-resistance to sunitinib, thereby accounting for the relatively short progression-free survival with second-line sunitinib. Currently, the presence of these multi-TKI resistant clones limits the overall survival of patients with advanced GIST.

Various agents have been tested as salvage therapy for patients with imatinib- and sunitinib-resistant GIST. Sorafenib, a multi-targeted kinase inhibitor with a spectrum of drug targets similar to sunitinib has been tested in the third- or fourth-line setting, yielding promising results in phase 2 studies. Notably, the progression-free survival of patients with TKI-resistant GIST in these studies was similar to that seen with second-line sunitinib.(13-15) Because sorafenib targets both angiogenesis-related kinases (VEGFRs) and the pathogenetic kinases found in GIST (KIT or PDGFRA), the molecular basis for sorafenib efficacy in this setting remains unknown.(16) In addition, only limited profiling of the activity of sorafenib against secondary mutations associated with drug-resistant GIST has been performed to date.(17, 18) Specifically, sorafenib has only been tested against the following KIT secondary mutations: V654A, T670I and D820Y.

To explore the molecular mechanisms responsible for sorafenib clinical activity against TKI-resistant GIST, we profiled the drug against a panel of KIT and PDGFRA mutant kinases expressed by transient transfection of a reference cell line. For comparison, we tested the potency of imatinib in the same experiments. This approach allowed us to compare the results to our previous work where we profiled sunitinib using the same methodology. (6) To verify our results, we also performed head-to-head comparisons of imatinib, sunitinib, and sorafenib in our isogenic cell models. In addition, we used imatinib-sensitive and imatinib-resistant GIST cell lines to further corroborate our results.

Our results indicate that sorafenib has good IC₅₀ potency against all imatinib-resistant mutations, with the exception of mutations involving codon 816 (exon 17, activation loop) and PDGFRA codon 842 (exon 18, activation loop). These results provide a potential mechanistic basis for the activity of sorafenib against drug-resistant GIST. In addition, our data suggest that the use of sorafenib in the first- or second-line setting might circumvent or prevent drug resistance mutations and yield improved clinical results.

Materials and Methods

Reagents and antibodies

Imatinib and sorafenib were purchased from LC Laboratories (Woburn, MA). Polyclonal rabbit antibody to KIT was from DAKO (Carpinteria, CA). Polyclonal rabbit antibodies to phospho-KIT Y721 (cat #3391), phospho-KIT Y703 (cat #3073), phospho-AKT S473 (cat #9271), total AKT (cat #9272), phospho-S6 S235/236 (cat #2211), and mouse monoclonal antibody to total S6 (cat #2317) were from Cell Signaling (Beverly, MA). Mouse monoclonal antibody to actin (cat #A4700) was from Sigma (St. Louis, MO). For PDGFRA immunoprecipitation experiments, we used rabbit polyclonal anti-PDGFRA antibody (Santa Cruz Biotechnology, SC-20, Santa Cruz, CA) and Protein A/G beads (Santa Cruz). For detection of phospho-PDGFRA and total PDGFRA we used anti-phosphotyrosine monoclonal antibody (PY-20, 1:500, BD Transduction Labs, Sparks, Maryland) and anti-PDGFRA rabbit polyclonal antibody (SC-20, 1:500, Santa Cruz), respectively. KIT immunoprecipitation experiments were performed as previously described.⁽⁶⁾ For detection of phospho- and total-KIT, we used rabbit polyclonal

antibody to P-KIT Tyr 719 (Cell Signaling Technology, cat#3391, 1:500, Danvers, MA) or total KIT (Santa Cruz, C-19, 1:500), respectively.

Sensitivity of Kinase Mutants to TKIs in Vitro

Chinese hamster ovary (CHO) cells were purchased from the American Tissue Type Collection (Manassas, VA) at the start of the study. CHO cells were transiently transfected with mutated *KIT* or *PDGFRA* cDNA constructs and treated with various concentrations of sorafenib, sunitinib or imatinib as previously described.(6) The common exon 11 mutation V560D was selected as a prototypic primary *KIT* exon 11 mutation and representative exon 13, 14, and 17 mutations were chosen as secondary mutations. Experiments involving recombinant DNA were performed using biosafety level 2 conditions in accordance with published guidelines.

Several GIST cell lines were established by the study authors (GIST882, GIST48, GIST430, and GIST-T1/829 by Dr. Fletcher, and GIST-T1 parental line by Dr. Taguchi). At the start of this study, all lines were credentialed by Sanger sequencing, confirming presence of unique *KIT* mutations that differ between the lines, and were also validated by 250K Nsp SNP profiling, demonstrating identity of origin with the primary tumor cultures (GIST882, GIST430, GIST48) or early-passage cell line cultures (GIST-T1) from which these immortal cell lines were established. The GIST-T1 cell line was established from an untreated GIST, and the GIST48 and GIST430 cell lines were established from imatinib-resistant clinically-progressing GISTs as previously

described.(5, 19) The cell lines were re-credentialed using the above procedures every 3 months during the study. GIST-T1/829 is a novel subline established by culturing GIST-T1 in incrementally increasing concentrations of imatinib: this subline contains the same *KIT* exon 11 mutation as parental GIST-T1, coupled *in cis* with a secondary A829P kinase-domain mutation. Protein lysates from transfected CHO cells or GIST cell lines were prepared and subjected to immunoprecipitation using anti-KIT or anti-PDGFR α antibodies followed by sequential immunoblotting for phospho-KIT or total KIT, or phosphotyrosine or total PDGFR α , respectively, as previously reported.(6, 20, 21) Densitometry was performed to measure drug effect, using Photoshop CS4 software (San Jose, CA) to quantify the level of phospho-KIT or phospho-PDGFR α normalized to total protein. Densitometry data was analyzed using CalcuSyn 2.1 software (Biosoft, Cambridge, UK) to mathematically determine the IC₅₀ values. The Wilcoxon Rank Sum Test was used to compare the IC₅₀ values of imatinib and sorafenib for a given mutation.

RESULTS

In-vitro Measure of IC₅₀ Activity of Sorafenib or Imatinib against Specific Mutants

We first assessed the potency of sorafenib against the three most common KIT genotypes found in GIST: KIT exon 11-mutant, KIT exon 9-mutant, and WT KIT. For purposes of comparison with previous publications and standardization of our subsequent experiments with double mutant isoforms, we chose the common exon 11 mutation V560D as a prototypic primary *KIT* mutation and used imatinib as the comparator TKI.

Sorafenib potently inhibited the KIT exon 11 V560D kinase with an IC_{50} of <100 nM. Sorafenib was significantly less potent against ligand-activated wild-type KIT with an IC_{50} value of approximately 2700 nM, which was similar to the IC_{50} of 3400 nM obtained for imatinib (Figure 1 panel A, Table 1). Sorafenib inhibited the KIT exon 9 mutant kinase with an IC_{50} of approximately 1800 nM, whereas the IC_{50} for imatinib was approximately 3970 nM (Figure 1 panel B, Table 1).

Sorafenib potently inhibited the phosphorylation of KIT exon 11 double mutants in which the second mutation occurred in the drug/ATP binding site of the receptor, including V560D + V654A (exons 11 + 13) and V560D + T670I (exons 11 + 14). These double mutants were strongly or completely resistant to imatinib (Figure 1 panel A, Table 1).

KIT exon 11-mutant kinases with a secondary mutation in the activation loop had strong *in vitro* resistance to imatinib, with IC_{50} values ranging from 1990-4000 nM. In contrast, with the exception of V560D + D816H, all of these compound mutant kinases were sensitive to sorafenib, with IC_{50} values ranging from 100-480 nM. The IC_{50} for V560D + D816H was 1930 nM. Resistance to sorafenib was also seen with KIT D816V, which is a primary activating mutation in AML and mast cell neoplasms, and an uncommon secondary mutation in GIST. The isolated D816V mutation was extremely resistant to imatinib and sorafenib, with IC_{50} values of > 5000 nM for both drugs (Figure 1 panel A, Table 1).

Although some KIT exon 9-mutant GISTs exhibit primary imatinib resistance, in many cases secondary drug resistance develops through the acquisition of mutations that are identical to those seen in imatinib-resistant GISTs with KIT exon 11 mutations. We tested the potency of sorafenib against KIT exon 9-mutant kinases with secondary V654A, D820G or D816H mutations and found IC_{50} values of 590 nM, 1380 nM, and 1820 nM, respectively. Consistent with previous results, the IC_{50} for imatinib against exon 9-mutant kinases with secondary V654A, D820G or D816H mutations was 3100 nM, 2640 nM, and 4930 nM, respectively (Figure 2A, table 1).

We also tested the potency of sorafenib in inhibiting the phosphorylation of wild-type PDGFRA, as well as the mutations PDGFRA V561D and deletion DIMH842-845 (Figure 2B, table 2). V561D is a relatively common primary PDGFRA mutation located in the receptor juxtamembrane domain encoded by exon 12, and is homologous to KIT V560D. The DIMH842-845 deletion is located in the activation loop of PDGFRA. Imatinib and sorafenib have similar potencies against these three PDGFRA isoforms ($IC_{50} < 100$ nM).

D842V, which is the most common primary *PDGFRA* mutation in GISTs, resides in the activation loop encoded by exon 18 and confers imatinib resistance when present as either a primary or a secondary mutation. Both the primary D842V and the V561D + D842V mutant kinases were insensitive to sorafenib in our in-vitro experiments (IC_{50} of 1280-3100 nM Fig 1 panel C, Table 2). This level of activity was similar to that seen for imatinib.

We have previously evaluated the activity of imatinib or sunitinib against our panel of mutations using the same experimental methods.(6) Notably, the imatinib IC_{50} values in the present studies are identical to those we previously reported. To further confirm our current results, we directly compared the potency of imatinib, sunitinib, or sorafenib in the same experiment. For these confirmatory experiments, we expressed the following mutant kinases: V560D + V654A, V560D + T670I, V560D + D816H, and V560D + N822K. Both sorafenib and sunitinib were potent inhibitors of V560D + V654A with IC_{50} s of <100 and 560 nM, respectively, whereas imatinib was significantly less effective (IC_{50} 1570 nM) (data not shown). Both sorafenib and sunitinib also had potent activity against V560D + T670I (IC_{50} s of 100-200 nM), whereas imatinib had no activity against this particular mutant kinase (IC_{50} >5000 nM). V560D + D816H was resistant to all drugs, with IC_{50} s of >1000nM, 2000nM and 2000 nM, respectively, for sunitinib, sorafenib, and imatinib. Another activation loop mutant, V560D + N822K, was very resistant to sunitinib (IC_{50} of >1000 nM) and imatinib (IC_{50} 2820 nM), but sensitive to sorafenib (IC_{50} 480 nM).

These results for imatinib and sunitinib are very similar to our previous published results.(6) Therefore, for comparative purpose, we have tabulated our current imatinib and sorafenib data with our previously reported sunitinib data to allow the relative comparison of the potency of these three TKIs against GIST-associated mutations, including isolated primary as well as primary + secondary mutations (Tables 1-2).

Comparative Biochemical Activity of Imatinib and Sorafenib in GIST cell lines

To confirm these findings in a GIST cell context, we tested the relative potency with which imatinib and sorafenib inhibited KIT kinase activity and downstream signaling in GIST cell lines. These included GIST-T1 cells with a primary exon 11 mutation alone (GIST-T1), and GISTs with primary exon 11 mutations coupled with secondary kinase domain mutations V654A (GIST430), D820A (GIST48), and A829P (GIST-T1/829) (Fig 3).(6, 19)

Consistent with our results against the isolated exon 11 V560D mutation expressed in CHO cells, both imatinib and sorafenib had similar potency against the KIT exon 11-mutant GIST-T1 cells ($IC_{50} < 100$ nM). In addition, imatinib and sorafenib were equally potent at inhibiting activation of KIT-dependent signaling pathways, as assessed by inhibition of phosphorylation of AKT (serine 473) and S6 (S253/236). By contrast, KIT and AKT were potently inhibited by sorafenib ($IC_{50} < 100$) but not imatinib ($IC_{50} > 1000$) in a GIST-T1 subline with the known imatinib-resistance secondary mutation, A829P.

The GIST430 cell line, derived from an imatinib-resistant clinical specimen, is heterozygous for a *KIT* exon 11 deletion mutation and the exon 13 V654A substitution (both on the same allele).(5) The IC_{50} for imatinib was approximately 750 nM. Notably, this concentration is almost 10-fold higher than that necessary to inhibit exon 11-mutant KIT kinase in the GIST-T1 cell line. In contrast, sorafenib was a substantially more potent inhibitor of the KIT oncoproteins in GIST430 cells, with an IC_{50} of < 100 nM. Consistent with these results, sorafenib was also more potent than imatinib for inhibition of AKT and S6.

The GIST48 cell line, also derived from an imatinib-resistant clinical specimen, is homozygous for a primary *KIT* exon 11 V560D mutation and heterozygous for a secondary exon 17 D820A mutation.(5) The imatinib IC₅₀ for this cell line was approximately 150 nM, but even at a dose of 1000 nM, KIT was only 60% inhibited. Sorafenib was significantly more potent than imatinib, with 85% inhibition of KIT phosphorylation using doses as low as 100 nM. Likewise, sorafenib treatment was substantially more effective than imatinib at inhibiting phosphorylation of AKT.

Discussion

Molecular mechanisms resulting in imatinib resistance have been delineated in GIST patients, and these mechanisms differ between cases of primary (or early) versus secondary (or delayed) resistance.(5, 8, 22, 23) Primary imatinib resistance, defined as progression during the first 6 months of treatment, is typically found in GIST with following genotypes: KIT exon 9-mutant, PDGFRA D842V-mutant GIST, or WT GIST. In the case of KIT exon 9-mutant or PDGFRA D842V-mutant GIST, this is likely due to relative or absolute resistance of these kinases to imatinib at clinically achievable drug levels. WT GIST is a heterogeneous set of tumors and sensitivity to imatinib is likely related in part to the degree that the tumor is actually dependent upon KIT activation for growth and survival.(23, 24)

Secondary imatinib resistance, defined as resistance that develops after 6 months or more of therapy, is much more common and is typically associated with acquisition of additional KIT kinase mutations. Notably, these mutations tend to cluster in two distinct domains of the protein: the ATP/drug binding pocket encoded by exons 13 and 14, and

the extended activation loop encoded by exons 17 and 18. These mutations are invariably found on the same allele as the primary KIT activation mutation. Mutation of *KIT* exons 13 or 14 confers extreme imatinib resistance. Various mutations of *KIT* exon 17 and 18 cause a range of resistance, from mild/moderate to extreme/absolute resistance.(5, 7, 8, 22, 23, 25, 26)

Sunitinib has been shown to be clinically effective for the treatment of imatinib-resistant GIST and is now established as second-line therapy.(9) Sunitinib, like imatinib, potently inhibits KIT and PDGFRs. One major difference between these two drugs is that sunitinib also targets VEGFR, while imatinib does not.(27) Theoretically, the activity of sunitinib against imatinib-resistant tumors might be due to targeting KIT and/or VEGFR. Sunitinib potently targets KIT mutant kinases with secondary mutations of the ATP/drug binding pocket. However, sunitinib has little significant clinical activity against KIT mutant kinases with secondary mutations of the activation loop.(6) To date, the only generally recognized mechanism of sunitinib resistance in GIST is the acquisition of KIT activation loop mutations.(6, 12) The contribution of VEGFR inhibition to the overall clinical activity of sunitinib against imatinib-resistant GIST remains unknown.

Sorafenib, a bi-aryl urea small molecular kinase inhibitor (Figure 4A), has potent activity against KIT, VEGFRs, FLT3, and PDGFRA/B tyrosine kinases. In addition, sorafenib has weak activity against certain intracellular serine/threonine kinases, including RAF1 and BRAF.(16) The similar target profiles of sunitinib and sorafenib, as well as the commercial availability of sorafenib, has helped drive several phase 2 clinical studies of sorafenib for treatment of imatinib-resistant GIST.

Kindler et al. reported the final results of a phase 2 consortium study of sorafenib for drug-resistant GIST. The original study was for patients with documented progression on imatinib. However, following FDA approval of sunitinib as a second line treatment for GIST, the study protocol was amended to require tumor progression after both imatinib and sunitinib therapy. All patients were treated with sorafenib 400 mg bid as the target starting dose. Overall, 38 patients were enrolled at 6 centers (6 imatinib-resistant, 32 imatinib/sunitinib-resistant). The disease control rate was 68% (13% PR: 1 imatinib-resistant, 4 imatinib+sunitinib-resistant; 55% SD: 3 imatinib-resistant, 18 imatinib+ sunitinib resistant). Median progression-free and overall survival was 5.2 and 11.6 months, respectively. This treatment regimen was associated with a greater than 50% rate of grade 3-4 toxicity (e.g. hand-foot syndrome 45%) requiring at least one dose reduction in 63% of patients. (13) Park et al. reported the results of a phase 2 study of sorafenib as third-line treatment. The overall disease control rate was 65% (10% PR, 55% SD). The median progression free survival was 4.6 months and the median overall survival had not been reached with a median followup of 7.5 months.(15)

There is also experience using sorafenib a fourth line therapy after progression or intolerance during prior imatinib, sunitinib and nilotinib therapy. In a retrospective report, 32 patients were treated with standard dose sorafenib (400 mg bid). The overall tumor control rate was 63% (19% PR, 44% SD). Median progression-free and overall survival were 4.6 and 10.4 months, respectively.(14)

Notably, the disease control rate and survival data for sorafenib in the third or fourth line settings are comparable with those reported for sunitinib in the second line setting (sunitinib disease control rate 65%, median PFS 5.5 months, median OS 17.2

months).(9) Regorafenib, a close analogue of sorafenib (Figure 4A), is also effective for treating imatinib and sunitinib resistant GISTs, with a progression free survival of 10 months in a phase 2 study.(28)

The most common grade 3-4 adverse events in GIST patients treated with sorafenib included hand-foot skin reaction (16%), anemia (7%), elevated liver enzymes or bilirubin (7%), hypertension (5%), and fatigue (5%). This spectrum and frequency of adverse events is similar to that reported with use of sorafenib in other malignancies.

We hypothesized that sorafenib would have a broader spectrum of activity against drug-resistant KIT mutations than imatinib or sunitinib, thus potentially explaining the activity of sorafenib in the treatment of advanced, drug-resistant GIST. Using an isogenic model to express single or compound KIT or PDGFRA mutations, we profiled the IC₅₀ activity of sorafenib across a broad panel of clinically relevant mutations. Sorafenib was found to be a potent inhibitor of KIT exon 11 mutant kinase with a potency that was equal to or greater than imatinib or sunitinib. Sorafenib was significantly more potent than imatinib against KIT kinase with secondary mutation of the ATP/drug binding pocket (V654A or T670I) and would be predicted to be clinically active against these mutations. However, sunitinib was the most potent of the three inhibitors against these particular mutations. Sorafenib was potent against secondary KIT mutations involving the activation loop with the notable exception of mutations involving codon 816 (D816H or D816V). Among the three inhibitors that we have profiled, sorafenib had the broadest spectrum of activity against drug-resistant mutations (see Figure 4B for comparative IC₅₀ activity).

Our results in the isogenic transient transfection model are in substantial agreement with those of Guo et al. and Guida et al. who profiled sorafenib against three secondary resistance mutation isoforms (V654A, T670I, D820Y) in non-GIST models.(17, 18) In addition, we obtained confirmatory results for the relative potency of imatinib and sorafenib using four different GIST cell models. Based on our results, we believe that inhibition of KIT kinase activity is a major determinant of clinical activity of sorafenib against multi-TKI resistant GIST.

We also profiled the activity of sorafenib against primary and secondary PDGFRA mutations associated with GIST. Imatinib and sorafenib had equivalent potency against PDGFRA WT, V561D, or deletion DIMH842-845 isoforms. However, neither drug has significant activity against PDGFRA D842V, either as an isolated primary mutation or when combined with a primary V561D mutation. These results are consistent with reports by Lierman *et al.* and von Bubnoff *et al.* using clinical samples or *in vitro* cell models to test the activity of sorafenib against imatinib-resistant FIP1L1-PDGFRA mutants.(29-31)

In most reported series of imatinib-resistant GIST, there is an approximately equal frequency of ATP binding pocket and activation loop mutations.(23) Importantly, individual patients often have multiple drug-resistant tumors, and these lesions can differ in their secondary mutations.(25) Thus, sunitinib may only be effective against half of the lesions in any given patient (*i.e.* the cells with secondary ATP binding pocket mutations). Based on our studies, sorafenib would be predicted to be active against the majority of imatinib-resistant tumors, with the exception of those lesions with secondary mutation of KIT codon 816. Presumably, the lack of activity of sorafenib against KIT

D816V and PDGFRA D842V is due to a lack of drug binding to these kinases when they are strongly stabilized in the active conformation by mutation of these aspartic acid residues.

Therefore, our data suggest that sorafenib might be a better agent for second-line treatment of imatinib-resistant GIST than the current standard agent, sunitinib. This prediction is also supported by the reported clinical activity of sorafenib in the third- or fourth-line setting that is comparable to that seen with sunitinib in the second-line setting.

Despite the promising activity of sorafenib for drug-resistant GIST, the manufacturers of sorafenib have chosen to suspend testing of this agent in GIST, and instead proceed with clinical development of the highly related compound, regorafenib.(28) This switch in drug development strategy occurred during the course of the current study. Regorafenib has now been tested in a phase 2 study where a 55% clinical benefit rate was seen (9% PR, 46% SD). The median progression free survival was 10 months.(28) Based on these results, regorafenib has been studied in a randomized, double blind, placebo controlled phase 3 study. This study is fully accrued and analysis of the results is expected during the latter half of 2012. Because sorafenib and regorafenib only differ by the presence of one side chain fluorine molecule, our studies with sorafenib may also be relevant to the interpretation of ongoing phase 2 and 3 studies of regorafenib (Figure 4A).

Our data suggest that sorafenib (or related compounds such as regorafenib) might be superior to imatinib in the front-line setting, as these agents would be predicted to suppress many of the drug-resistant clones that lead to clinical imatinib-resistance.

Based on experimental models and clinical studies of TKI-treatment of CML, front-line treatment with second-generation TKIs that suppress the development of drug resistance clones may contribute to more durable disease control than front-line imatinib.(32-34) However, sorafenib and regorafenib are associated with a higher incidence of grade 3-4 adverse events requiring dose interruption and/or dose reduction than imatinib. Comparative clinical trials of sorafenib or structurally related compounds in the first- or second-line treatment of advanced GIST could be considered to help further optimize medical therapy for this disease.

Grant Support: Supported in part from funding from a Veterans Affairs Merit Review Grant (M.C. Heinrich), the Life Raft Group (M.C. Heinrich, J.A. Fletcher), the GIST Cancer Research Fund (M.C. Heinrich, J.A. Fletcher), GI SPORE 1P50CA127003 (J.A. Fletcher), BP Lester Foundation (M.C. Heinrich), the Virginia and Daniel K. Ludwig Trust for Cancer Research (J.A. Fletcher), Fundación Alfonso Martín Escudero (A. Marino-Enriquez), and Cathay General Hospital Research Fund (C.-W. Liang).

Reference List

- (1) Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. *Annu Rev Pathol* 2008;3:557-86.
- (2) Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. *Lancet* 2007;369:1731-41.
- (3) Blanke CD, Demetri GD, von MM, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. *J Clin Oncol* 2008;26:620-5.
- (4) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. *J Clin Oncol* 2010;28:1247-53.

- (5) Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol* 2006;24:4764-74.
- (6) Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. *J Clin Oncol* 2008;26:5352-9.
- (7) Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. *Clin Cancer Res* 2006;12:1743-9.
- (8) Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. *Clin Cancer Res* 2005;11:4182-90.
- (9) Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 2006;368:1329-38.
- (10) Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. *Clin Cancer Res* 2009;15:5902-9.
- (11) Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. *Proc Natl Acad Sci U S A* 2009;106:1542-7.
- (12) Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. *Int J Clin Oncol* 2009;14:143-9.
- (13) Kindler HL, Campbell NP, Wroblewski K, Maki RG, D'Adamo D, Chow WA, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. *Journal Clinical Oncology* 29, 2011. 2011.
Ref Type: Abstract
- (14) Reichardt P, Montemurro M, Gederblom H, Blay J, Rutkowski P, Bui B, et al. Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis. *J Clin Oncol* [27], 15s. 2011.
Ref Type: Abstract

- (15) Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. *Invest New Drugs* 2012.
- (16) Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004;64:7099-109.
- (17) Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. *Clin Cancer Res* 2007;13:3363-9.
- (18) Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. *Clin Cancer Res* 2007;13:4874-81.
- (19) Taguchi T, Sonobe H, Toyonaga S, Yamasaki I, Shuin T, Takano A, et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. *Lab Invest* 2002;82:663-5.
- (20) Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA Mutations In Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity To Imatinib. *J Clin Oncol* 2005;23:5357-64.
- (21) Heinrich MC. Molecular basis for treatment of gastrointestinal stromal tumours. *European Journal of Cancer Supplements* 2006;4:10-8.
- (22) Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. *Gastroenterology* 2005;128:270-9.
- (23) Gramza AW, Corless CL, Heinrich MC. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. *Clin Cancer Res* 2009;15:7510-8.
- (24) Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. *Nat Rev Cancer* 2011;11:865-78.
- (25) Liegl B, Kepten I, Le C, Zhu M, Demetri G, Heinrich M, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. *J Pathol* 2008;216:64-74.
- (26) Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. *Cancer Res* 2004;64:5913-9.

- (27) Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor beta in Preclinical Models of Human Small Cell Lung Cancer. *Mol Cancer Ther* 2003;2:471-8.
- (28) George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, et al. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). *J Clin Oncol* 29, 2011. 2011.

Ref Type: Abstract

- (29) Lierman E, Folens C, Stover EH, Mentens N, Van MH, Scheers W, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. *Blood* 2006;108:1374-6.
- (30) Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. *Leukemia* 2009;23:845-51.
- (31) von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thone S, Aberg E, et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. *Oncogene* 2011;30:933-43.
- (32) Kantarjian HM, Hochhaus A, Saglio G, De SC, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *Lancet Oncol* 2011;12:841-51.
- (33) O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Res* 2005;65:4500-5.
- (34) Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2010;362:2260-70.

1° Mutation	2° Mutation	Imatinib	Sorafenib	Sunitinib
V560D	None	<100	<100	<100
V560D	V654A	1600	560**	<100
V560D	T670I	>5000	200**	<100
V560D	D816H	1990	1930	>1000
V560D	D820A	4000	<100	ND
V560D	D820G	3255	480**	>1000
V560D	N822K	2820	480**	>1000
V560D	Y823D	2100	280**	>1000
WT	None	3400	2700	<100
D816V	None	>5000	>5000	>1000
KIT insAY502-503	None	3970	1829**	<100
KIT insAY502-503	V654A	3100	590**	100
KIT insAY502-503	D816H	4930	1820**	>1000
KIT insAY502-503	D820G	2640	1380**	ND

Table 1. Biochemical IC₅₀ values for inhibition of KIT kinase activity in transfected cells. The values for imatinib, sorafenib, and sunitinib represent the biochemical IC₅₀ expressed in nM units. The values for imatinib, sorafenib, and sunitinib represent the biochemical IC₅₀ expressed in nM units for the listed single mutant or compound mutant kinases. WT indicates the results for wild-type (unmutated), KIT ligand-stimulated KIT kinase. The IC₅₀ values for imatinib and sorafenib are from direct head to head comparison from a minimum of three replicate experiments. The IC₅₀ values for sunitinib are from a previous publication from our group.(6) ND= not determined. ** = p<0.05 sorafenib IC₅₀ compared with imatinib IC₅₀.

Table 2. Biochemical IC₅₀ values for inhibition of PDGFRA kinase activity in transfected cells. The values for imatinib, sorafenib, and sunitinib represent the biochemical IC₅₀ expressed in nM units. The values for imatinib, sorafenib, and sunitinib represent the biochemical IC₅₀ expressed in nM units for the listed single mutant or compound mutant kinases. WT indicates the results for wild-type (unmutated), PDGF-AA ligand-stimulated PDGFRA kinase. The IC₅₀ values for imatinib and sorafenib are from direct head to head comparisons from a minimum of three replicate experiments. The IC₅₀ values for sunitinib are from a previous publication from our group.(6) ND= not determined. The IC₅₀ for imatinib was not significantly different than the IC₅₀ for sorafenib for any of these mutant kinases

1° Mutation	2° Mutation	Imatinib	Sorafenib	Sunitinib
WT	None	<100	<100	<100
V561D	None	<100	<100	<100
V561D	D842V	3100	3100	>1000
Del DIMH842-845	None	<100	<100	ND
D842V	None	1700	1280	>1000

Figure Legends

Figure 1. Comparative biochemical activity of imatinib versus sorafenib for inhibiting KIT activity in transiently transfected cells. CHO cells were transiently transfected and protein lysates from transfected cells were prepared and subjected to immunoprecipitation using anti-KIT antibody followed by sequential immunoblotting for phospho-KIT (P-KIT) or total KIT (KIT), respectively as previously reported. Representative results from a minimum of three replicate experiments for the comparative activity of imatinib or sorafenib for inhibiting WT (unmutated, ligand-stimulated KIT), isolated KIT exon 11 mutation (V560D), isolated KIT exon 17 mutation (D816V), or compound mutations of V560D with a secondary imatinib-resistance mutation are shown.

Figure 2. Comparative biochemical activity of imatinib versus sorafenib for extracellular KIT mutants or PDGFRA mutant kinases in transiently transfected cells. CHO cells were transiently transfected and protein lysates from transfected cells were prepared and subjected to immunoprecipitation using anti-KIT or anti-PDGFRA antibodies followed by sequential immunoblotting for phospho-KIT (P-KIT) or total KIT (KIT), or phosphotyrosine (P-PDGFRA) or total PDGFRA (PDGFRA), respectively, as previously reported. **Panel A:** Representative results from a minimum of three replicated experiments of the comparative activity of imatinib or sorafenib for inhibiting the isolated KIT exon 9 mutation insertion 502-503 AY or compound mutations of KIT exon 9 with a secondary imatinib-resistant mutation are shown. **Panel B:** Representative results from a minimum of three replicate experiments of the comparative activity of imatinib or sorafenib for inhibiting WT (unmutated, PDGF-AA ligand-stimulated PDGFRA), isolated PDGFRA exon 12 (V561D) or exon 18 mutant kinases (D842V, deletion DIMH842-845), or the compound mutant kinase V561D + D842V are shown.

Figure 3. Comparative activity of imatinib and sorafenib for inhibition of KIT kinase and activation of downstream signaling pathways in GIST cell lines. GIST cell lines were treated with imatinib or sorafenib for 6 hours and then harvested for protein lysates. Whole cell lysates were immunoblotted and the membrane was probed with antibodies to activated (p-KIT, p-AKT, p-S6) and total forms of KIT, AKT and S6. The bottom frame contains the results for β -actin, which was used as a loading control.

Figure 4.

A) Chemical structures of sorafenib and regorafenib.

B) Graphical comparison of the potency of imatinib, sunitinib, and sorafenib for imatinib-resistant KIT mutations (cellular IC₅₀). The left-most stick figure depicts the protein structure of the KIT protein, with location and frequency of primary GIST mutations to the left of the figure and the location of critical functional domains indicated on the right side of the figure (JM=juxtamembrane domain). The right-most stick figure is an exploded view of a portion of the cytoplasmic domain, with labeling to indicate the location of critical exons (colored rectangles). The location and composition of amino acid substitutions associated with secondary KIT kinase mutations are indicated on the right of the exploded stick figure (e.g. V654A). The traffic light boxes to the right of the figure indicate sensitivity of the indicated mutations to imatinib (IM), sunitinib (SU) or sorafenib (SOR). Drug sensitive mutations were defined as those with a cellular IC₅₀ in our model system of <200 nM for sunitinib and <1000 nM for imatinib and sorafenib.

FIGURE 1




Figure 2a





Figure 2b







Figure 4A

Sorafenib



Regorafenib




Figure 4B

